Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 6.67%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including significant revenue growth, reduced operating expenses, and progress in licensing and commercialization efforts across various segments. However, challenges such as a decline in cash position and uncertainties in revenue predictions were noted. Overall, the positive highlights outweigh the lowlights, indicating a promising outlook for the company.Company Guidance
During VolitionRX Limited's First Quarter 2025 Earnings Conference Call, the company outlined significant financial progress and strategic goals for the year. Operating expenses were reduced by 35% compared to the first quarter of 2024, leading to a 48% decrease in net cash used in operating activities, which totaled $4.3 million. Revenue for the quarter was nearly $0.25 million, marking a 44% increase year-over-year, with the first revenue recorded from human product sales. Cash and cash equivalents were reported at $2.6 million. The company secured $2.3 million from a registered direct offering, $1.6 million in non-dilutive loan financing, and finalized a convertible loan note for $6.25 million for additional financial support. VolitionRX aims to achieve cash flow neutrality for the full year 2025 and is actively pursuing licensing discussions with over 10 companies, targeting a total addressable market of approximately $25 billion annually in cancer and sepsis diagnostics. The company is also making strides in the veterinary market and advancing its Nu.Q Discover program with collaborations in the pharmaceutical sector, which are expected to significantly contribute to revenue growth.Significant Revenue Growth
VolitionRX reported a 44% increase in revenue compared to Q1 2024, including the first revenue recorded for sales of human products.
Operating Expenses Reduction
Total operating expenses for the quarter declined 35% compared to Q1 2024, reflecting cost reductions across all spending categories.
Successful Licensing Discussions
VolitionRX is in confidential discussions with over 10 companies to license their products, with seven companies having a combined market value exceeding $600 billion.
Nu.Q Platform Developments
The company is progressing in the commercialization of their Nu.Q platform in the human diagnostic market, with potential market opportunities in cancer and sepsis diagnostics.
First Revenue from CE Marked Product
VolitionRX recorded its first revenue from sales of its CE Marked Nu.Q NETs automated product in Europe.
Expansion of Nu.Q Vet
Nu.Q Vet Cancer Test is expanding its global reach, with significant partnerships in place to enhance canine cancer screening.
Nu.Q Discover Revenue Potential
Nu.Q Discover biomarkers are being utilized in a human clinical study sponsored by a leading pharmaceutical company, expected to generate significant revenue.
VNRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VNRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.45 | $0.43 | -4.44% |
Mar 31, 2025 | $0.57 | $0.52 | -8.77% |
Nov 14, 2024 | $0.72 | $0.68 | -5.56% |
Aug 14, 2024 | $0.55 | $0.57 | +3.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does VolitionRX (VNRX) report earnings?
VolitionRX (VNRX) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is VolitionRX (VNRX) earnings time?
VolitionRX (VNRX) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNRX EPS forecast?
VNRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.05.